合成大麻素污染长效抗凝灭鼠剂引发严重凝血病暴发
本文为伊利诺伊毒物中心2018年3月10日至8月1日报告的暴露回顾性分析。纳入疑似合成大麻素使用、长效抗凝灭鼠剂检测阳性且存在凝血病(出血表现或INR>2)的患者,共178例。多数为男性(73%),中位年龄32岁(IQR 25-40),88%就诊时INR>10,70%出现血尿,63%有背/腰/腹痛;18例定性抗凝检测均为溴敌隆阳性,另检出敌鼠(10/18)和溴鼠隆(1/18)。106例接受静脉维生素K1,未报告不良反应;41例(22%)自动离院,38例(21%)再住院,自动离院者再住院风险为其他去向者的1.6倍;颅内出血占3%,5例死亡中4例存在颅内出血。
要点
- 疑似合成大麻素使用且INR>2、无其他凝血病解释即可纳入本病;88%患者就诊时INR>10。
- 出血表现多样:70%血尿、63%背/腰/腹痛;颅内出血占总病例3%,5例死亡中4例有颅内出血。
- 18例定性抗凝检测全部溴敌隆阳性,另检出敌鼠10/18、溴鼠隆1/18,提示多种长效抗凝灭鼠剂污染。
- 106例接受静脉维生素K1,未报告不良反应或过敏样反应。
- 41例(22%)自动离院,38例(21%)再住院;自动离院者再住院风险为其他去向者的1.6倍。
适用人群与场景
- 2018年3月10日至8月1日向伊利诺伊毒物中心报告的暴露病例,疑似合成大麻素使用、长效抗凝灭鼠剂检测阳性且存在凝血病(出血表现或INR>2)者。
- 无长效抗凝灭鼠剂检测结果时,疑似合成大麻素使用、INR>2且无其他凝血病解释者纳入。
- 确证性长效抗凝灭鼠剂检测阴性者排除。
诊断标准与关键阈值
- 凝血病定义为出血体征或症状,或国际标准化比值(INR)>2。
- 疑似合成大麻素使用定义为治疗团队成员怀疑使用或患者自述使用。
处置流程与药物剂量
- 106例接受静脉维生素K1;原文未写明剂量、频次与疗程。
- 患者常需血液制品、凝血因子替代及大剂量维生素K1以稳定病情。
红旗征与不能漏的情况
- 颅内出血占总病例3%,5例死亡中4例存在颅内出血。
- 就诊时INR>10者占88%。
研究设计与关键结果
- 回顾性分析,178例符合纳入标准;男性73%,中位年龄32岁(IQR 25-40),多数就诊于皮奥里亚县(35%)和库克县(31%)医院,中位住院3天(IQR 2-4)。
- 88%患者就诊时INR>10;18例定性抗凝检测全部溴敌隆阳性,敌鼠10/18、溴鼠隆1/18。
- 63%有背、腰或腹痛,70%有血尿;106例接受静脉维生素K1,未报告不良反应或过敏样反应。
- 41例(22%)自动离院,38例(21%)研究期间再住院;自动离院者再住院可能性为其他去向者的1.6倍。
- 颅内出血占总病例3%,5例死亡中4例存在颅内出血。
证据类型、等级与局限
- 证据类型:回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对疑似合成大麻素使用且INR>2、无其他凝血病解释的患者,应按长效抗凝灭鼠剂中毒评估,即使无明确出血表现。
- 患者出血部位多样,常需血液制品、凝血因子替代及大剂量维生素K1稳定病情;106例接受静脉维生素K1未报告不良反应或过敏样反应。
- 自动离院者再住院风险为其他去向者的1.6倍,提示对离院患者需关注再住院风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Objective: To describe a large regional poison center's experience managing an outbreak of long-acting anticoagulant rodenticide (LAAR) poisoning associated with synthetic cannabinoid (SC) use.Methods: This is a retrospective review of exposures reported to the Illinois Poison Center between March 10 and August 1, 2018. All cases coded as exposure to Δ9-tetrahydrocannabinol homologs were identified. Patients with suspected SC use, positive LAAR testing, and coagulopathy (signs or symptoms of bleeding or international normalized ratio [INR] > 2) were included. If confirmatory LAAR testing was performed and resulted as negative, the patient was excluded from this analysis. In the absence of LAAR testing, patients with suspected SC use, an INR >2, and no alternative explanation of coagulopathy were included. Suspected SC use was defined as use suspected by a member of the treating team or reported by the patient. Presenting signs and symptoms, laboratory findings, management, healthcare utilization, outcomes, and disposition of patients affected by this outbreak were reported.Results: One hundred seventy-eight cases met inclusion criteria. Most patients were male (73%) and young to middle-aged (median age 32, IQR 25-40). Most presented to hospitals in Peoria (35%) and Cook (31%) counties. Median hospitalization was three days (IQR 2-4). Eighty-eight percent of patients presented with an INR >10. Eighteen cases had qualitative anticoagulant testing, all of which were positive for brodifacoum. Other identified LAARs included difenacoum (10/18) and bromadiolone (1/18). Sixty-three percent of patients had back, flank or abdominal pain; 70% of patients presented with hematuria. One hundred six cases received IV vitamin K1; no adverse or anaphylactoid reactions were reported. Forty-one (22%) patients left AMA. Thirty-eight patients (21%) were re-hospitalized during the study period. Patients leaving AMA were 1.6 times more likely to be re-hospitalized than patients with other dispositions. Intracranial hemorrhage, present in 3% of total cases, was present in 4 of 5 fatalities.Conclusions: We describe an outbreak of multiple LAARs contaminating SCs. Patients presented with bleeding from varied sites, often required blood products, factor replacement, and high dose vitamin K1 for stabilization.
参考来源
- Devgun JM, Rasin A, Kim T, et al. An outbreak of severe coagulopathy from synthetic cannabinoids tainted with Long-Acting anticoagulant rodenticides. Clin Toxicol (Phila). 2019. PMID: 31797705. doi:10.1080/15563650.2019.1690149
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。